Abstract
The two estrogen receptors (ERs), ERαand ERβ, are molecular targets of the xenoestrogen class of endocrine disruptors. These receptors are ligand-activated transcription factors regulated by naturally occurring estrogens. Activation of mammalian ERs by xenoestrogens has been associated with both adverse and beneficial effects. A more informed appraisal of the likely risks and benefits of xenoestrogens requires an understanding of their biological effects at the molecular level. Receptor binding and reporter-based transient transfection assays indicate that some compounds, including the phytoestrogens genistein and coumestrol, activate ERβpreferentially, suggesting that this receptor subtype may play a predominant role in mediating the effects of these compounds. We review recent advances in our understanding of the responses of mammalian cells to estrogenic compounds and describe an approach to decipher these effects at the molecular level.
Similar content being viewed by others
References
Adlercreutz H, Fotsis T, Bannwart C, Wahala K, Makela T, Brunow G & Hase T (1986) Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens, in urine of women on various habitual diets. J. Steroid Biochem. 25: 791-797.
Adlercreutz H, Hockerstedt K, Bannwart C, Bloigu S, Hamalainen E, Fotsis T & Ollus A (1987) Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin (SHBG). J. Steroid Biochem. 27: 1135-1144.
An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N & Leitman DC (2001) Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J. Biol. Chem. 276: 17808-17814.
Ariyo AA & Villablanca AC (2002) Estrogens and lipids. Can HRT designer estrogens, and phytoestrogens reduce cardiovascular risk markers after menopause? Postgrad. Med. 111: 23-30.
Aumais JP, Lee HS, Lin R & White JH (1997) Selective interaction of HSP90 with an estrogen receptor ligand-binding domain containing a point mutation. J. Biol. Chem. 272: 12229-12235.
Axelson M & Setchell KD (1981) The excretion of lignans in rats-evidence for an intestinal bacterial source for this new group of compounds. FEBS Lett. 123: 337-342.
Bannwart C, Adlercreutz H, Wahala K, Kotiaho T, Hesso A, Brunow G & Hase T (1988) Identification of the phyto-oestrogen 3',7-dihydroxyisoflavan, an isomer of equol, in human urine and cow's milk. Biomed. Environ. Mass. Spectrom. 17: 1-6.
Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J & Nilsson S (1998) Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol. 54: 105-112.
Beato M, Chalepakis G, Schauer M & Slater EP (1989) DNA regulatory elements for steroid hormones. J. Steroid Biochem. 32: 737-747.
Beekman JM, Allan GF, Tsai SY, Tsai MJ & O'Malley BW (1993) Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol. Endocrinol. 7: 1266-1274.
Berry M, Metzger D & Chambon P (1990) Role of the two activating domains of the oestrogen receptor in the cell-type and promotercontext dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 9: 2811-2818.
Bertazzi A, Pesatori AC, Consonni D, Tironi A, Landi MT & Zocchetti C (1993) Cancer incidence in a population accidentally exposed to 2,3,7,8-tetrachlorodibenzo-para-dioxin. Epidemiology 4: 398-406.
Bertazzi PA, Bernucci I, Brambilla G, Consonni D & Pesatori AC (1998) The Seveso studies on early and long-term effects of dioxin exposure: a review. Environ. Health Perspect. 106: 625-633.
Bertucci F, Houlgatte R, Benziane A, Granjeaud S, Adelaide J, Tagett R, Loriod B, Jacquemier J, Viens P, Jordan B, Birnbaum D & Nguyen C (2000) Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum. Mol. Gen. 9: 2981-2991.
Bowtell DD (1999) Options available-from start to finish-for obtaining expression data by microarray. Nat. Genet. 21: 25-32.
Brown PO & Botstein D (1999) Exploring the new world of the genome with DNA microarrays. Nat. Genet. 21: 33-37.
Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA & Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753-758.
Couse JF, Hewitt SC, Bunch DO, Sar M, Walker VR, Davis BJ & Korach KS (1999) Postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta. Science 286: 2328-2331.
Cowley SM & Parker MG (1999) A comparison of transcriptional activation by ER alpha and ER beta. J. Steroid Biochem. Mol. Biol. 69: 165-175.
Davis SR, Dalais FS, Simpson ER & Murkies AL (1999) Phytoestrogens in health and disease. Recent Prog. Horm. Res. 54: 185-210.
Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P & Mark M (2000) Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 127: 4277-4291.
Enmark E & Gustafsson J-A (1998) Estrogen receptor beta-a novel receptor opens up new possibilities for cancer diagnosis and treatment. Endocr. Rel. Cancer 5: 213-222.
Fiorelli G, Gori F, Frediani U, Franceschelli F, Tanini A, Tosti-Guerra C, Benvenuti S, Gennari L, Becherini L & Brandi ML (1996) Membrane binding sites and non-genomic effects of estrogen in cultured human pre-osteoclastic cells. J. Steroid Biochem. Mol. Biol. 59: 233-240.
Gustafsson JA (1999) Estrogen receptor beta-a new dimension in estrogen mechanism of action. J Endocrinol 163: 379-383.
He TC, Zhou S, da Costa LT, Yu J, Kinzler KW & Vogelstein B (1998) A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U S A 95: 2509-2514.
Hulten K, Aldercreutz H, Winkvist A, Lenner P, Hallmans G & Agren A (1998) Low levels of phyto-oestrogens in blood as risk factors for breast cancer. COST 916 Workshop, 34 pp.
Ingram D, Sanders K, Kolybaba M & Lopez D (1997) Case-control study of phyto-oestrogens and breast cancer. Lancet 350: 990-994.
Klinge CM (2001) Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 29: 2905-2919.
Knoblauch R & Garabedian MJ (1999) Role for HSP90-associated co-chaperone p23 in estrogen receptor signal transduction. Mol. Cell Biol. 19: 3748-3759.
Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL & Manolagas SC (2001) Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell104: 719-730.
Kraus WL & Kadonaga JT (1998) p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. Genes Dev. 12: 331-342.
Kraus WL, McInerney EM & Katzenellenbogen BS (1995) Liganddependent, transcriptionally productive association of the aminoand carboxyl-terminal regions of a steroid hormone nuclear receptor. Proc. Natl. Acad. Sci. USA 92: 12314-12318.
Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA & Smithies O (1998) Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc. Natl. Acad. Sci. USA 95: 15677-15682.
Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S & Gustafsson JA (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138: 863-870.
Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S & Gustafsson JA (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 93: 5925-5930.
Kuiper GG & Gustafsson JA (1997) The novel estrogen receptorbeta subtype: potential role in the cell-and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett. 410: 87-90.
Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B & Gustafsson JA (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139: 4252-4263.
Lazennec G, Alcorn JL & Katzenellenbogen BS (1999) Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation. Mol. Endocrinol. 13: 969-980.
Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS & Smithies O (1993) Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc. Natl. Acad. Sci. USA 90: 11162-11166.
McDonnell DP, Clemm DL, Hermann T, Goldman ME & Pike JW (1995) Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol 9: 659-669.
McInerney EM & Katzenellenbogen BS (1996) Different regions in activation function-1 of the human estrogen receptor required for antiestrogen-and estradiol-dependent transcription activation. J. Biol. Chem.271: 24172-24178.
McInerney EM, Weis KE, Sun J, Mosselman S & Katzenellenbogen BS (1998) Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology 139: 4513-4522.
McKenna NJ & O'Malley BW(2002) Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108: 465-474.
Moggs JG & Orphanides G (2001) Estrogen receptors: orchestrators of pleiotropic cellular responses. EMBO Rep. 2: 775-781.
Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, Pestell RG, Hinds PW, Dowdy SF, Brown M & Ewen ME (1997) Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol. Cell Biol. 17: 5338-5347.
Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M & Gustafsson JA (2001) Mechanisms of estrogen action. Physiol. Rev. 81: 1535-1565.
Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ & Scanlan TS (1997) Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277: 1508-1510.
Pennie WD (2000) Use of cDNA microarrays to probe and understand the toxicological consequences of altered gene expression. Toxicol. Lett. 112-113: 473-477.
Pennie WD, Aldridge TC & Brooks AN (1998) Differential activation by xenoestrogens of ER alpha and ER beta when linked to different response elements. J. Endocrinol. 158: R11-R14.
Pennie WD, Woodyatt NJ, Aldridge TC & Orphanides G (2001) Application of genomics to the definition of the molecular basis for toxicity. Toxicol. Lett. 120: 353-358.
Pettersson K & Gustafsson JA (2001) Role of estrogen receptor beta in estrogen action. Annu. Rev. Physiol. 63: 165-192.
Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA & Carlquist M (1999) Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 18: 4608-4618.
Price KR & Fenwick GR (1985) Naturally occurring oestrogens in foods-A review. Food Addit. Contam. 2: 73-106.
Setchell KD, Bull R & Adlercreutz H (1980) Steroid excretion during the reproductive cycle and in pregnancy of the vervet monkey (Cercopithecus aethiopus pygerythrus). J. Steroid Biochem. 12: 375-384.
Setchell KD & Cassidy A (1999) Dietary isoflavones: Biological effects and relevance to human health. J. Nutr. 129: 758S-767S.
Setchell KD, Lawson AM, Borriello SP, Harkness R, Gordon H, Morgan DM, Kirk DN, Adlercreatz H, Anderson LC & Axelson M (1981) Lignan formation in man-microbial involvement and possible roles in relation to cancer. Lancet 2: 4-7.
Shang Y & Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science 295: 2465-2468.
Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA & Greene GL (1998) The structural basis of estrogen receptor/ coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95: 927-937.
Soulez M & Parker MG (2001) Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling. J. Mol. Endocrinol. 27: 259-274.
Strauss L, Santti R, Saarinen N, Streng T, Joshi S & Makela S (1998) Dietary phytoestrogens and their role in hormonally dependent disease. Toxicol. Lett. 102-103: 349-354.
Webb P, Lopez GN, Uht RM & Kushner PJ (1995) Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 9: 443-456.
Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S & Kushner PJ (1999) The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol. Endocrinol. 13: 1672-1685.
Wong E (1975) In: JB Harbourne, TJ Mabry & H Mabry (eds) The Flavonoids. (pp. 748-800). Academic Press, New York.
Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D & Gronemeyer H (1996) A canonical structure for the ligandbinding domain of nuclear receptors. Nat. Struct. Biol. 3: 87-94.
Young RK, Cailleau RM, Mackay B & Reeves WJ, Jr. (1974) Establishment of epithelial cell line MDA-MB-157 from metastatic pleural effusion of human breast carcinoma. In Vitro 9: 239-245.
Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D, Hodgin J, Shaul PW, Thoren P, Smithies O, Gustafsson JA & Mendelsohn ME (2002) Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 295: 505-508.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Murphy, T.C., Orphanides, G. Characterisation of the molecular responses to xenoestrogens using gene expression profiling. Phytochemistry Reviews 1, 199–208 (2002). https://doi.org/10.1023/A:1022511501282
Issue Date:
DOI: https://doi.org/10.1023/A:1022511501282